Clinical Trials
4 trialsNCT02744612 2025-03-26
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT02824029 2025-02-17
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02869633 2023-10-23
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT02626884 2021-04-08
IRENO
University of Cologne
Phase 2 Completed